Psilocybin Safety and Screening: What to Expect Before a Retreat

Illustrative stock photo from Pexels, not a Life Synergy session.

If you are considering a retreat, you deserve more than a beautiful photo and a quick yes. You deserve a real conversation about whether the setting, the support, and the timing make sense for you.

Some of the questions may feel personal. That is understandable. The point is not to judge you or make you tell a perfect story. The point is to avoid making important decisions with half the information.

This guide explains the questions worth expecting, the details worth sharing, and the questions you should ask back. It describes general safety considerations, not a verified checklist of Life Synergy's services or clinical capabilities.

Why should a retreat ask so many questions?

Psilocybin experiences can be unpredictable. Fear, confusion, panic, nausea, and increases in blood pressure or heart rate are among the risks described by the National Center for Complementary and Integrative Health. Your expectations, mood, surroundings, and the amount taken can influence the experience. A supportive setting matters, but it does not remove those risks.¹

Research safety guidelines place screening alongside preparation, informed consent, a carefully managed environment, and follow-up. Screening is one part of the picture, not a stamp that says nothing can go wrong.²

A responsible conversation should leave room for three outcomes: proceeding within an appropriate setting, getting additional professional assessment, or not proceeding. A pause is not a personal failure. You should not feel pressured to make your history sound simpler so a booking can go ahead.

Also, a research study, a regulated service center, and a retreat are not interchangeable. Their staff qualifications, legal requirements, medical resources, and participant criteria may differ. Oregon's regulated psilocybin system, for example, requires a preparation session and a safety and support plan. Those are Oregon-specific requirements, not proof that an international retreat follows the same framework.³

What mental health history should I disclose?

Share diagnoses, past episodes, hospitalizations, and symptoms that may never have received a formal label. Research safety guidelines recommend screening for personal and family histories of psychotic disorders and bipolar disorder. NCCIH warns that psilocybin is not safe for people with psychotic conditions such as schizophrenia and some other serious psychiatric conditions.^1,2

Questions you may hear include:

• Have you ever experienced psychosis, hallucinations outside substance use, or beliefs that others found disconnected from reality?
• Have you ever had mania or hypomania, or been told you might have bipolar disorder?
• Have there been periods of very little sleep together with unusual energy, impulsivity, or risky behavior?
• Have you been hospitalized for a mental health concern?
• Have close relatives experienced psychosis or bipolar disorder?
• Are you currently having thoughts of suicide, self-harm, or harming someone else?

These are reasons for careful assessment, not invitations to diagnose yourself from a checklist. Family history can matter even when you have never had the same diagnosis. The research guidelines recommend conservative family-history screening, but their trial exclusions should not be mistaken for one universal rule for every program.²

Bipolar disorder deserves particular care. In a survey of people with self-reported bipolar disorder who had used psilocybin, some reported new or increased manic symptoms, sleep difficulties, and anxiety. The study was observational and self-reported, so it cannot predict one person's outcome or establish safety for a retreat. Small or emerging studies are not a reason to bypass specialist advice.⁴

If you are in an immediate crisis or might act on thoughts of harming yourself or someone else, seek urgent local help. A retreat is not an emergency response service. Oregon's official information identifies current thoughts of harm to self or others as a potential reason for ineligibility in its regulated system.³

Which physical health issues matter?

Do not assume that being active, eating well, or feeling generally healthy answers the physical safety questions.

Psilocybin can temporarily raise blood pressure and heart rate. A cardiovascular review notes that many studies exclude people with pre-existing cardiovascular disease, which limits how confidently their safety findings can be applied to those people.^1,5

Disclose heart or blood vessel conditions, high blood pressure, rhythm problems, fainting, previous stroke, seizures, and any significant ongoing illness. Share recent hospital care, surgery, unexplained symptoms, and relevant test results if a qualified professional requests them. A thorough health history is part of the research screening approach.^2,5

Ask who evaluates this information and when they refer a guest to an independent healthcare professional. Depending on your history, that professional may need to consider an examination or testing. A questionnaire alone cannot establish cardiovascular safety. The examinations and blood pressure thresholds used in a specific study should not become a do-it-yourself clearance test.^2,5

If you develop new symptoms between applying and traveling, update the program. Yesterday's intake answers may no longer describe today's situation.

What should I say about medications and supplements?

Everything you take is relevant to an honest screening conversation: prescriptions, over-the-counter medicines, supplements, and other substances. Include the name, dose, frequency, purpose, recent changes, and anything you have recently stopped.

Lithium is a particularly important disclosure. An analysis of online reports found seizures associated with combining lithium and classic psychedelics. These self-selected reports cannot establish the chance of a seizure for an individual, but they raise a serious safety concern. Oregon's official information lists lithium use within the previous 30 days as a potential reason for ineligibility in its system. That is not an instruction to stop lithium or wait 30 days on your own.^3,6

Antidepressants need a more nuanced conversation. They are not all the same, and it is misleading to treat every antidepressant as having the same interaction. A recent scoping review found mixed evidence about effects on the experience and important gaps in the interaction literature. Some monitored studies involving SSRIs or SNRIs were reassuring, but those results do not establish that every medication combination is safe in a retreat.⁷

Monoamine oxidase inhibitors, stimulants, combinations of medications, and supplements should also be disclosed. The same review discusses a serious adverse event involving psilocybin mushrooms, an MAOI, and an amphetamine. Research safety guidelines also flag supplements such as St. John's wort and 5-HTP for screening. Do not use this article as a complete interaction list.^2,7

Stopping an antidepressant can itself cause problems, including withdrawal symptoms and a return of symptoms. Medication changes belong with your prescriber, not a sales conversation or an online checklist.⁷

What about pregnancy or breastfeeding?

Disclose pregnancy, the possibility of pregnancy, and breastfeeding before considering participation.

The MotherToBaby fact sheet states that human studies have not established risks for several pregnancy outcomes and that psilocybin mushrooms have not been studied during breastfeeding. Missing evidence is not evidence of safety. Research safety guidelines exclude pregnant participants.^2,8

Pregnancy and breastfeeding are reasons to defer participation and discuss your circumstances with your healthcare professional rather than rely on reassurance from a retreat. This article cannot supply a safe interval for breastfeeding or a safe exposure level.⁸

How should I understand contraindications without an oversimplified list?

A contraindication is a reason an intervention should not be used in a particular situation. In this field, the strength of the evidence and the rules of a program can differ. Some concerns lead to exclusion, some require further assessment, and others involve major unknowns.

This table is a guide to the conversation, not a personal eligibility tool.

No table can cover every medical condition or drug combination. Not seeing your situation here is not the same as being cleared.

What else should I disclose honestly?

Your history is more than a diagnosis and a medication list. Tell the program about previous psychedelic experiences, especially severe panic, prolonged distress, persistent perceptual changes, or an experience that led to emergency care. Research guidelines recognize both acute distress and the possibility of longer-lasting adverse effects.²

Also be open about current alcohol or drug use, dependence, and recent changes in use. Substance-use history is included in research safety screening. Do not hide it because you worry the answer will complicate your application.²

Other practical details help the program understand what support you may need:

• Significant recent stress, loss, or conflict.
• Current sleep patterns and whether they have changed sharply.
• Mobility, sensory, communication, or accessibility needs.
• Boundaries around touch, privacy, and group participation.
• Who you can contact afterward, and whether your home environment feels supportive.
• Whether anyone is pressuring you to attend.

You do not need to share every detail with every staff member. Ask who sees your information, how it is stored, and what may be shared in an emergency. You can ask for a private screening conversation and an explanation of why a question is being asked.

What questions should I ask the retreat in return?

Screening should work in both directions. Here are direct questions worth asking before committing money or travel:

1. Who reviews my intake answers, and what are their qualifications and limits?
2. What situations lead you to decline or defer a guest?
3. When do you require independent medical or psychiatric advice?
4. How do you handle medications without asking guests to manage changes themselves?
5. What preparation happens before the experience, and how is informed consent explained?
6. How many staff will be present, and what support can they actually provide?
7. What is the emergency plan, who calls for help, and how is outside medical care reached?
8. What are the boundaries around touch, privacy, and withdrawing consent?
9. What follow-up is available, and what happens if I struggle after returning home?
10. What legal framework applies in this location, and what happens to my booking if screening shows the retreat is unsuitable?

Preparation, informed consent, trained support, emergency planning, and follow-up are important safeguards in research guidance. However, a retreat should describe its own resources clearly rather than borrow the language of a clinical trial to imply equivalent care.²

Be cautious if the answers are only reassuring slogans. You are looking for specifics, including an honest explanation of what staff cannot do. Promising that a natural substance is risk-free contradicts the adverse effects described by NCCIH.¹

How can I prepare for a useful screening conversation?

Write down your health history, medications and supplements, recent changes, previous experiences, and the questions you do not want to forget. If a diagnosis is uncertain, say so. If you do not know a family detail, say that too.

You can start simply: "I want to be honest about my history before we talk about dates. Who should review this information, and what might mean this is not the right setting for me?"

Give yourself permission to take time. A discovery call can help clarify the program, but it is not a substitute for professional health advice or a guarantee of acceptance.

The most useful answer is not always yes. Sometimes it is "not now," "we need more information," or "this is outside our scope." That kind of honesty is worth listening to.